Latest Non-Hodgkin lymphoma Stories
Careful screening is recommended to protect Non-Hodgkin’s Lymphoma patients against this dangerous side effect of rituximab. Raleigh, NC (PRWEB) February 22,
Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb.
A European study of compounds designed to stimulate stem cells finds that biologically similar versions work as well as the original. Raleigh, NC (PRWEB) February
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system.
SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan.
- The act of sweetening by admixture of some saccharine substance.